FindTrial
Sign In

Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-503062-72-00
Acronym
INCB 54707-207
Enrollment
66
Registered
2023-10-31
Start date
2023-11-23
Completion date
2025-10-02
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Spontaneous Urticaria

Brief summary

Change from baseline in the UAS7, defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at Week 12.

Detailed description

Proportion of participants who achieve UAS7 ≤ 6 (controlled disease) at Week 12., Time to first achievement of UAS7 ≤ 6 (controlled disease) during the PC period., Proportion of participants with UAS7 = 0 at Week 12.

Interventions

DRUGPovorcitinib matching placebo.
DRUGPovorcitinib

Sponsors

Incyte Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change from baseline in the UAS7, defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at Week 12.—

Secondary

MeasureTime frame
Proportion of participants who achieve UAS7 ≤ 6 (controlled disease) at Week 12., Time to first achievement of UAS7 ≤ 6 (controlled disease) during the PC period., Proportion of participants with UAS7 = 0 at Week 12.—

Countries

Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026